文献速递消化系统肿瘤

衰老癌相关成纤维细胞经乳酸介导的代谢-表观遗传重编程驱动早期胰腺癌淋巴结转移

Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring.
PubMed 文献 · Cancer Discov · 2026-01-01

本研究探讨早期胰腺导管腺癌(PDAC)淋巴结转移(LNM)的机制,发现衰老癌相关成纤维细胞(senCAF)通过增加葡萄糖代谢和乳酸产生,激活乳酸化介导的丝氨酸代谢以保护淋巴内皮细胞免受氧化应激,并发现引流淋巴结中CCR4+调节性T细胞在淋巴管周围聚集形成免疫抑制微环境。高通量药物筛选确定chidamide可选择性清除senCAF,减缓肿瘤进展并提高化疗免疫治疗疗效,随后在转移性PDAC患者中启动临床试验(chidamide联合白蛋白紫杉醇/吉西他滨加抗PD-1/CTLA-4)并报告初步有希望的结果。

要点

  • senCAF通过乳酸介导的代谢-表观遗传重编程驱动早期PDAC淋巴管重塑和淋巴结转移。
  • chidamide可选择性清除senCAF,减缓肿瘤进展并提高化疗免疫治疗疗效。
  • 临床试验初步显示chidamide联合方案在转移性PDAC中具有潜力。

核心结论

  • 衰老癌相关成纤维细胞(senCAF)驱动早期PDAC淋巴管重塑和淋巴结转移,chidamide清除senCAF可改善化疗免疫治疗疗效。

研究设计与样本

  • 本研究为实验性研究,包括机制探索、高通量药物筛选和临床试验(chidamide联合白蛋白紫杉醇/吉西他滨加抗PD-1/CTLA-4)在转移性PDAC患者中报告初步结果。

主要发现

  • senCAF增加葡萄糖代谢和乳酸产生,激活乳酸化介导的丝氨酸代谢以保护淋巴内皮细胞免受氧化应激。
  • 引流淋巴结中CCR4+调节性T细胞在淋巴管周围聚集,建立免疫抑制的淋巴管周围微环境。
  • 高通量药物筛选确定chidamide可选择性清除senCAF,减缓肿瘤进展并提高化疗免疫治疗疗效。

关键数值与推荐

  • 临床试验(chidamide联合白蛋白紫杉醇/吉西他滨加抗PD-1/CTLA-4)在转移性PDAC患者中报告初步有希望的结果。

临床怎么用

  • 靶向清除senCAF(如chidamide)可能作为改善PDAC化疗免疫治疗疗效的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Lymph node (LN) metastasis (LNM) in early-stage pancreatic ductal adenocarcinoma (PDAC) predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. In this study, we demonstrated that senescent cancer-associated fibroblasts (senCAF) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ regulatory T cells from the draining LNs accumulated around lymphatic vessels, which established an immunosuppressive perilymphatic niche. High-throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression, and improved chemoimmunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti-PD-1/CTLA-4) in patients with metastatic PDAC and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemoimmunotherapy efficacy. SIGNIFICANCE: Our findings have revealed a closed link between cellular senescence, metabolic reprograming, and spatial immunosuppressive niche and PDAC metastasis, offering the potential senolytic drugs to improve chemoimmunotherapy efficacy in patients with PDAC.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhou T, Yan J, Mao G, et al. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Cancer Discov. 2026. PMID: 41891402. doi:10.1158/2159-8290.CD-25-1627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。